1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,504 | 0,548 | 16:27 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CERENO SCIENTIFIC Aktie jetzt für 0€ handeln | |||||
| 17.06. | Cereno Scientific AB: Cereno Scientific AB (publ) publishes report from the Annual General Meeting 2026 | 276 | GlobeNewswire (Europe) | Today, June 17, 2026, Cereno Scientific AB (publ) held its Annual General Meeting at the MAQS Advokatbyrå's premises at Masthamnsgatan 13 in Gothenburg, Sweden. Chairperson of the Annual General Meeting... ► Artikel lesen | |
| 27.05. | Cereno Scientific AB: Cereno Scientific Publishes Interim Report for Q1 2026 | 723 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 11.05. | Cereno Scientific AB: Cereno Scientific Enters Collaboration with PHA Europe & Global to Advance Patient-centered Drug Development in Pulmonary Hypertension | 431 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced a collaboration... ► Artikel lesen | |
| 10.04. | Cereno Scientific to Participate at Nordic Health Summit Japan and ChinaBio Partnering Forum 2026 | 1 | Cision News | ||
| 04.04. | Cereno Scientific AB: Cereno Scientific Highlights Strategic Value of Meeting Primary Endpoint of Safety and Tolerability of 12-month CS1 Data in PAH | 845 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today provides additional... ► Artikel lesen | |
| 31.03. | Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program | 377 | PR Newswire | GOTHENBURG, Sweden, March 31, 2026 /PRNewswire/ -- Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare... ► Artikel lesen | |
| 27.03. | Cereno Scientific: Stifel Initiates Coverage with Buy Rating and Price Target of SEK 20 | 1 | Cision News | ||
| 23.03. | Cereno Scientific - Inflection points coming into view | 493 | Edison Investment Research | Cereno Scientific's FY25 results mark a strategically productive period, with multiple value inflection points coming into focus in FY26. With the Phase IIb start for lead asset CS1 expected in Q226... ► Artikel lesen | |
| 19.03. | Cereno Scientific - capital markets day highlights (Video) | 477 | Edison Investment Research | In this video, we go behind the scenes at Cereno Scientific's capital markets day, speaking with key stakeholders, including company leadership, industry experts and patients living with pulmonary arterial... ► Artikel lesen | |
| 17.03. | Cereno Scientific Receives Approval to Initiate FDA-aligned Phase I Pharmacokinetic Study of CS014 Supporting Phase II Development in PH-ILD | 1.239 | PR Newswire | GOTHENBURG, Sweden, March 17, 2026 /PRNewswire/ -- Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare... ► Artikel lesen | |
| 27.02. | Cereno Scientific AB: Cereno Scientific Publishes Year-end Report for 2025 (January 1 - December 31, 2025) | 846 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 20.02. | Cereno Scientific - CMD reaffirms shifting focus to clinical delivery | 460 | Edison Investment Research | Cereno Scientific's recent capital markets day (CMD) centered on CS1's progression from early clinical validation into Phase IIb development, a key inflection for the investment thesis. Supported by... ► Artikel lesen | |
| 04.02. | Cereno Scientific broadens development focus for CS014 to pulmonary hypertension associated with interstitial lung disease | 628 | PR Newswire | GOTHENBURG, Sweden, Feb. 4, 2026 /PRNewswire/ -- Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare... ► Artikel lesen | |
| 04.02. | Cereno Scientific AB: Cereno Scientific broadens development focus for CS014 to pulmonary hypertension associated with interstitial lung disease | 609 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that... ► Artikel lesen | |
| 03.02. | Cereno Scientific AB: Cereno Scientific Provides Update on Expanded Access Program for CS1 - initial learnings expected in Q1 2026 | 394 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced the... ► Artikel lesen | |
| 02.02. | Cereno Scientific Announces Program and Speakers for the Capital Markets Day on February 5, 2026 | 1 | Cision News | ||
| 28.01. | Cereno Scientific to Present CS014 Data and Participate in Panel at Scientific Conference PVRI 2026 Dublin | 1 | Cision News | ||
| 14.01. | Cereno Scientific Announces First Peer-Reviewed Publication on HDAC Inhibitor CS014: Antithrombotic Efficacy Without Bleeding Risk Supports Broad Potential in Cardiopulmonary Diseases | 387 | PR Newswire | GOTHENBURG, Sweden, Jan. 14, 2026 /PRNewswire/ -- Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare... ► Artikel lesen | |
| 12.01. | Cereno Scientific - Entering a value inflection phase | 501 | Edison Investment Research | We refresh our investment case for Cereno Scientific as the company enters a key value inflection period, with its lead asset CS1 expected to initiate a Phase IIb study in Q226, followed by Phase II... ► Artikel lesen | |
| 08.01. | Cereno Scientific AB: Cereno Scientific Receives approximately SEK 5 million Through Exercise of 728,957 Warrants by Arena Investors, LP | 444 | GlobeNewswire (Europe) | Cereno Scientific (Nasdaq First North: CRNO B) ("the Company"), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, announces... ► Artikel lesen |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ACTIVE BIOTECH | 0,509 | +1,80 % | XFRA NEW INSTRUMENTS AVAILABLE ON 03.06.2026 | The following instruments on XETRA do have their first trading 03.06.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 03.06.2026
Aktien
1 US3143521058 FedEx Freight Holding... ► Artikel lesen | |
| CANTARGIA | 0,166 | +0,12 % | Cantargia AB: Cantargia announces outcome in rights issue and resolves on a directed issue of warrants to Fenja Capital | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE... ► Artikel lesen | |
| QIAGEN | 34,220 | +4,94 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen vor Zahlen zum zweiten Quartal auf "Buy" belassen. Diese dürften sich im Rahmen der eigenen Vorgaben des Diagnostikspezialisten... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 132,91 | +0,02 % | Apogee Therapeutics: Hier dürfte zum US-Handelsstart heute die Post abgehen! | AbbVie steht laut einem Bericht kurz vor der Übernahme von Apogee Therapeutics für rund 10,9 Milliarden US-Dollar in bar. Der mögliche Aufschlag liegt bei etwa 60 Prozent. Weil die US-Börsen am Freitag... ► Artikel lesen | |
| ABSCI | 8,855 | +19,50 % | Morning Market Movers: Cuprina Holdings, CEA Industries, Absci, The Wendy's Company See Big Swings | MEMPHIS (dpa-AFX) - At 7:10 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 19,300 | -9,05 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering | ZUG, Switzerland, June 23, 2026 - MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and... ► Artikel lesen | |
| TANGO THERAPEUTICS | 28,970 | +2,04 % | Tango Therapeutics, Inc.: Tango Therapeutics Appoints Robert Azelby to Board of Directors | BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| EVOTEC | 4,900 | +4,21 % | Blockbuster, Gold und Insiderverkäufe - Bayer AG, Evotec, North Arrow Minerals | Der erneute israelische Angriff im Libanon blockiert die eh schon unsicheren US-Iran-Gespräche massiv. Da Teheran die Hisbollah im Libanon unterstützt und den Frieden mit den USA an einen Frieden zwischen... ► Artikel lesen | |
| BIONTECH | 78,90 | -1,00 % | Alarm bei BMW! Ausverkauf bei BioNTech! Unterbewertung bei Desert Gold Aktie! | Alarm bei BMW. Erst hat man Aktionäre mit einer Gewinnwarnung schockiert. Das Geschäft in China ist eingebrochen. Jetzt ziehen Analysten ihre Konsequenzen. Die Schätzungen und Kursziele werden reduziert.... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 311,78 | +2,10 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| RELAY THERAPEUTICS | 18,435 | +5,71 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 48,180 | -0,86 % | Hedge Fund and Insider Trading News: John Paulson, Warren Buffett, Ray Dalio, Brevan Howard, Rokos Capital Management, Noble Corp PLC (NE), Enliven Therapeutics Inc (ELVN), and More | ||
| RECURSION PHARMACEUTICALS | 3,200 | +1,27 % | Hauptversammlung von Recursion Pharmaceuticals: Aktionäre stimmen allen Vorschlägen zu | ||
| COGENT BIOSCIENCES | 37,280 | +2,67 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress | -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria... ► Artikel lesen | |
| BEAM THERAPEUTICS | 34,360 | +3,49 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen |
Das Unternehmen CERENO SCIENTIFIC AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,023 (-4,17 %) liegt der Kurs bei 0,518 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERENO SCIENTIFIC AB finden Sie auf Wallstreet Online.